JMP Securities downgraded shares of Vascular Biogenics (NASDAQ:VBLT) from an outperform rating to a market perform rating in a research report report published on Thursday morning.

A number of other equities research analysts also recently weighed in on VBLT. Piper Jaffray Companies downgraded Vascular Biogenics from an overweight rating to a neutral rating and set a $4.00 target price on the stock. in a report on Thursday. HC Wainwright downgraded Vascular Biogenics from a buy rating to a neutral rating and set a $3.00 target price on the stock. in a report on Thursday. ValuEngine raised Vascular Biogenics from a sell rating to a hold rating in a report on Friday, February 2nd. Finally, Zacks Investment Research downgraded Vascular Biogenics from a hold rating to a sell rating in a report on Friday, February 23rd. Two research analysts have rated the stock with a sell rating and four have assigned a hold rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $3.33.

How to Become a New Pot Stock Millionaire

Shares of Vascular Biogenics (NASDAQ VBLT) opened at $2.60 on Thursday. The firm has a market capitalization of $77.28, a price-to-earnings ratio of -3.29 and a beta of -2.44. Vascular Biogenics has a twelve month low of $2.30 and a twelve month high of $9.05.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. IFP Advisors Inc boosted its holdings in shares of Vascular Biogenics by 339.7% during the 4th quarter. IFP Advisors Inc now owns 19,567 shares of the biopharmaceutical company’s stock valued at $139,000 after acquiring an additional 15,117 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Vascular Biogenics during the 3rd quarter valued at $135,000. Alps Advisors Inc. acquired a new stake in shares of Vascular Biogenics during the 4th quarter valued at $234,000. ARK Investment Management LLC acquired a new stake in shares of Vascular Biogenics during the 4th quarter valued at $302,000. Finally, Raymond James & Associates boosted its holdings in shares of Vascular Biogenics by 71.5% during the 4th quarter. Raymond James & Associates now owns 55,466 shares of the biopharmaceutical company’s stock valued at $394,000 after acquiring an additional 23,124 shares in the last quarter. 5.61% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Vascular Biogenics (VBLT) Rating Lowered to Market Perform at JMP Securities” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2018/03/12/vascular-biogenics-vblt-rating-lowered-to-market-perform-at-jmp-securities.html.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.